Table 1.
Treatment response and FLT3 mutations of the 6 patients with FLT3-ITD-positive AML
| Caseno. | Sex/age | Karyotype | Additional mutations | Sorafenib maintenance | Follow-up post allo-HSCT (M) | Response | FLT3 mutation | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | AF | Relapse | AF | |||||||
| #1 | M/52 | 46, XY | None | Yes | 13.0 | CCR | FLT3-ITD | 0.62 | NA | |
| #2 | F/28 | 46, XY | TET2 | Yes | 8.0 | CCR | FLT3-ITD | 0.76 | NA | |
| #3 | M/39 | 47, XY, + 10 | DNMT3A, NPM1, SOCS1 | Yes | 13.5 | Relapse | FLT3-ITD | 0.52 | FLT3-ITD | 0.39 |
| #4 | F/23 | 46, XX, t(11;20)(p15;q11) | TET2, RUNX1 | Yes | 10.0 | Relapse | FLT3-ITD | 0.43 | FLT3-ITD + D835 | 0.30 |
| #5 | M/23 | 47, XY, + 8 | TET2 | Yes | 11.5 | Relapse | FLT3-ITD | 0.66 | FLT3-ITD | 0.41 |
| #6 | M/43 | 46, XY | EZH2, RUNX1, BCL6 | Yes | 7.0 | Relapse | FLT3-ITD | 0.75 | WT | |
Allo-HSCT allogenetic hematopoietic stem cell transplantation; M months; AF allele frequency; M male; CCR continued complete response; NA not available; F female; WT wild type